Management of heart failure with preserved ejection fraction

Heart failure with preserved ejection fraction is a highly heterogenous disease. There is emerging evidence that treatment should be tailored to the individual’s associated comorbidities No current algorithms exist for the management of heart failure with preserved ejection fraction. Conventional th...

Full description

Saved in:
Bibliographic Details
Published in:Australian prescriber 2020-02, Vol.43 (1), p.12-17
Main Authors: Gard, Emma, Nanayakkara, Shane, Kaye, David, Gibbs, Harry
Format: Article
Language:English
Subjects:
Amyloidosis
Beta blockers
Blood pressure
Cardiac arrhythmia
Cardiovascular disease
Comorbidity
Coronary vessels
Diabetes
Diuretics
Drug therapy
Dyspnea
Ejection fraction
Exercise
Heart failure
Hemodynamics
Hospitalization
Mortality
Obesity
Pulmonary arteries
Pulmonary hypertension
Quality of life
Vein & artery diseases
Weight control
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Heart failure with preserved ejection fraction is a highly heterogenous disease. There is emerging evidence that treatment should be tailored to the individual’s associated comorbidities No current algorithms exist for the management of heart failure with preserved ejection fraction. Conventional therapies used in heart failure with reduced ejection fraction are yet to show a mortality benefit Key treatment objectives include control of hypertension and fluid balance Common comorbidities include coronary artery disease, atrial fibrillation, obesity, diabetes, renal impairment and pulmonary hypertension. These comorbidities should be considered in all patients and treatment optimised
ISSN:0312-8008
1839-3942
DOI:10.18773/austprescr.2020.006